基础医学与临床 ›› 2019, Vol. 39 ›› Issue (6): 899-903.

• 短篇综述 • 上一篇    下一篇

非同源末端连接研究进展及其在肿瘤发生和治疗中的意义

李家丽,刘颖   

  1. 武汉大学生命科学学院;武汉大学医学研究院
  • 收稿日期:2019-04-02 修回日期:2019-04-16 出版日期:2019-06-05 发布日期:2019-06-04
  • 通讯作者: 李家丽 E-mail:15620954914@163.com
  • 基金资助:
    武汉大学实验技术项目

Research progress of non-homologous end joining and the value in tumorigenesis and therapy

Jia-Li LI1,Ying Liu   

  • Received:2019-04-02 Revised:2019-04-16 Online:2019-06-05 Published:2019-06-04
  • Contact: Jia-Li LI E-mail:15620954914@163.com
  • Supported by:
    Wuhan University Experiment Technology Project Funding

摘要: 双链DNA损伤修复(DDR)途径主要包括非同源末端连接(NHEJ)和同源重组(HR),其中非同源末端连接(NHEJ)是DNA双链断裂后主要的修复方式,在原发肿瘤的发生发展和变异中发挥关键调控作用。近年发现了NHEJ修复DNA损伤新的组分和分子机制,丰富了对NHEJ通路的认识。通过对NHEJ分子机制及相关肿瘤的研究,发现抑制NHEJ活性可提高肿瘤细胞对放化疗的敏感性,提示NHEJ通路可能成为肿瘤治疗的新靶点。

关键词: DNA损伤修复(DDR), 非同源末端连接(NHEJ), 同源重组(HR), 肿瘤

Abstract: The DNA double-strand break (DSB) repair pathway mainly comprises the non-homologous end joining (NHEJ) and the homologous recombination (HR). The NHEJ is the dominant repair method upon DSBs, which is critical for primary tumor development and evolution. In recent years, novel components and mechanisms for NHEJ were unveiled, which advances the understanding of the NHEJ pathway. Latest studies also showed the inhibition of NHEJ activity could sensitize tumor cells to chemo- and radio-therapies, indicating that NHEJ components might be potential targets for treating tumors.

Key words: DNA damage repair (DDR), non-homologous end joining (NHEJ), homologous recombination (HR), tumor

中图分类号: